Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. METHODS: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P<0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%). CONCLUSIONS: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [14]
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Research works printed but not linked: 2
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
Cited by
Items 701–800 of 1,025
D’Amico, A. G., Maugeri, G., Reitano, R., Bucolo, C., Saccone, S., Drago, F., & D’Agata, V. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0621-7 · Cited by 61
“However, to date, anti-VEGF therapy has demonstrated its efficacy to counteract ocular neovascularization only in 50 % of treated patients, suggesting that other pathogenic factors may play an important role in non-responders (Lin et al. 2011; Rey and Semenza 2010; Brown et al. 2006).”
BackgroundVEGF inhibitors for the treatment of neovascular age-related macular degeneration
Barakat, M. R., & Kaiser, P. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902855316 · Cited by 60
“The Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) study [26] and the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) study [27] were both Phase III, 2-year, randomized, double-masked clinical…”
BackgroundSelf-citationGeorge, P. P., Molina, J. D., & Heng, B. H. (2014) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.138615 · Cited by 66
“Evidence from observational studies and few randomized clinical trials (RCT’s) suggest that off-label bevacizumab is effective for the treatment of exudative AMD.”
BackgroundInfluentialSouied, E. H., Oubraham, H., Mimoun, G., Cohen, S. Y., Quere, S., & Derveloy, A. (2015) · Retina · doi:10.1097/iae.0000000000000548 · Cited by 59
Bloch, S. B., la Cour, M., Sander, B., Hansen, L. K. H., Fuchs, J., Lund‐Andersen, H., & Larsen, M. (2013) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02268.x · Cited by 60
“Intravitreal treatment with ranibizumab, a selective inhibitor of all isoforms of vascular endothelial growth factor A (VEGF), is associated with a vastly improved visual outcome that is sustained when injections are given repeatedly at fixed 4-week intervals (Brown et al. 2006; Rosenfeld et al. 2006).”
BackgroundResultInfluentialDietary modification and supplementation for the treatment of age-related macular degeneration
Broadhead, G., Grigg, J., Chang, A., & McCluskey, P. (2015) · Nutrition Reviews · doi:10.1093/nutrit/nuv005 · Cited by 65
Lin, J. D., Chang, J. S., & Smiddy, W. E. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.05.037 · Cited by 61
Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials
Ying, G., Maguire, M. G., Pan, W., Grunwald, J. E., Daniel, E., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., & Martín, D. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.10.003 · Cited by 67
Mecamylamine Suppresses Basal and Nicotine-Stimulated Choroidal Neovascularization
Kiuchi, K., Matsuoka, M., Wu, J., Silva, R. L. E., Kengatharan, M., Mary, V., Ueno, S., Yokoi, K., Khu, N. H., Cooke, J. P., et al. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0089 · Cited by 60
“Intraocular injections of the VEGF antagonists ranibizumab and bevacizumab have become the first-line treatment for CNV and have provided tremendous benefit to patients.(19,20) However, repeated intraocular injections carry small but definite risk.”
BackgroundSystemic Safety of Bilateral Intravitreal Anti–Vascular Endothelial Growth Factor Injections
Freund, K. B., & Vance, S. K. (2010) · Retina · doi:10.1097/iae.0b013e318203c0ef · Cited by 58
Keane, P. A., Patel, P. J., Ouyang, Y., Chen, F. K., Ikeji, F., Walsh, A. C., Tufail, A., & Sadda, S. R. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4846 · Cited by 63
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration
Mousa, S. A., & Mousa, S. S. (2010) · BioDrugs · doi:10.2165/11318550-000000000-00000 · Cited by 64
“Two cases of presumed endophthalmitis and one case of serious uveitis were reported in the high-dose ranibizumab group, while no such events occurred in the verteporfin or low-dose ranibizumab groups.([29]) More frequent administration (defined as <2 months mean inter-injection interval) of ranibizumab in the eye resu…”
BackgroundMethodCheung, C. M. G., Li, X., Mathur, R., Lee, S. Y., Chan, C. M., Yeo, I. Y. S., Loh, B. K., Williams, R. E., Wong, E. Y., Wong, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101057 · Cited by 60
Lanzetta, P., Mitchell, P., Wolf, S., & Veritti, D. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303394 · Cited by 63
Rufai, S. R., Almuhtaseb, H., Paul, R. M., Stuart, B. L., Kendrick, T., Lee, H., & Lotery, A. J. (2017) · Eye · doi:10.1038/eye.2017.67 · Cited by 64
Dalvin, L. A., Starr, M. R., Chehade, J. E. A., Damento, G. M., Garcia, M., Shah, S. M., Hodge, D. O., Meissner, I., Bakri, S. J., & Iezzi, R. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6891 · Cited by 59
Kaiser, P. K. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x167624 · Cited by 60
Self-citationCosta, R. A., Jorge, R., Calucci, D., Melo, L. A. S., Cardillo, J. A., & Scott, I. U. (2007) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0557-x · Cited by 64
Reznicek, L., Klein, T., Wieser, W., Kernt, M., Wolf, A., Haritoglou, C., Kampik, A., Huber, R. A., & Neubauer, A. S. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2640-4 · Cited by 57
“Therefore, OCT is becoming more and more relevant for ophthalmic diagnostics [1–5], and has increasing impact on therapy [6–10].”
BackgroundMatsumoto, H., Hoshino, J., Nakamura, K., Nagashima, T., & Akiyama, H. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06116-y · Cited by 57
Bevacizumab wirkt nicht toxisch auf Zellen des menschlichen Auge
Kernt, M., Welge‐Lüßen, U., Yu, A., Neubauer, A. S., & Kampik, A. (2007) · Der Ophthalmologe · doi:10.1007/s00347-007-1569-y · Cited by 57
Therapeutic targeting of the complement system in age‐related macular degeneration: a review
Troutbeck, R., Al‐Qureshi, S., & Guymer, R. H. (2012) · Clinical & Experimental Ophthalmology · doi:10.1111/j.1442-9071.2011.02581.x · Cited by 57
“Although these are effective modalities, a significant drawback in their utility is the need for repeated intraocular injection (and exposure to associated risks) to maintain therapeutic benefit.(25,26) Vascular endothelial growth factor trap is a new form of VEGF inhibitor currently in phase III clinical trial, and m…”
BackgroundGarg, S. J., Brod, R. D., Kim, D., Lane, R. G., Maguire, J. I., & Fischer, D. H. (2008) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2008.01710.x · Cited by 57
“Although the ANCHOR and MARINA studies reported no cases of RPE tears with ranibizumab (from a total of 758 eyes), there have been anecdotal reports of its occurence.(12,14,28,29) In the PDT trials with Visudyne (Novartis) (TAP and VIP studies), the incidence of RPE tears was not commented upon.”
Wickremasinghe, S. S., Xie, J., Lim, J., Chauhan, D. S., Robman, L., Richardson, A. J., Hageman, G., Baird, P. N., & Guymer, R. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6550 · Cited by 58
Ehlers, J. P., Petkovsek, D. S., Yuan, A., Singh, R. P., & Srivastava, S. K. (2015) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/23258160-20150323-05 · Cited by 57
Oishi, A., Shimozono, M., Mandai, M., Hata, M., Nishida, A., & Kurimoto, Y. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2034-4 · Cited by 57
“[14-16] The treatment enabled not only maintenance of vision but also improvement in patients with any subtype of AMD over a 24-month period.[14-16] Although the relatively high cost of the drug and the need for ongoing intravitreal injections are demanding,[17] no other treatment has achieved these levels of visual a…”
BackgroundXing, L., Dorrepaal, S. J., & Gale, J. S. (2014) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.03.009 · Cited by 59
Novel Drug Delivery Systems for Retinal Diseases
Lee, S. S., & Robinson, M. R. (2009) · Ophthalmic Research · doi:10.1159/000209665 · Cited by 65
“More recently, pharmaceutical intervention using angiostatic compounds has had a dramatic effect on the natural history of CNV and has improved or stabilized the visual acuity in a number of patients [”
BackgroundKhan, A. A., Dace, D. S., Ryazanov, A. G., Kelly, J., & Apte, R. S. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090836 · Cited by 64
“28 To test the effect of resveratrol on injury-induced angiogenesis in the eye, mice were treated with i) vehicle (25% EtOH), ii) resveratrol (22.5 mg/kg), or iii) resveratrol (45 mg/kg) 7 days before and after the laser-induced injury.”
MethodInfluentialLee, A., Day, A. C., Egan, C. A., Bailey, C., Johnston, R. L., Tsaloumas, M. D., Denniston, A. K., Tufail, A., Akerele, T., Al-Husainy, S., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.014 · Cited by 59
Sulzbacher, F., Kiss, C., Kaider, A., Eisenkoelbl, S., Munk, M. R., Roberts, P. K., Sacu, S., & Schmidt-Erfurth, U. M. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-9162 · Cited by 57
The Proteomic Landscape in the Vitreous of Patients With Age-Related and Diabetic Retinal Disease
Schori, C., Trachsel, C., Grossmann, J., Zygoula, I., Barthelmes, D., & Grimm, C. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24122 · Cited by 63
Issues with Intravitreal Administration of Anti-VEGF Drugs
Schargus, M., & Фрингс, А. (2020) · Clinical ophthalmology · doi:10.2147/opth.s207978 · Cited by 62
Arias, L., Mitjana, J. M. C., Casas, L., Aumatell, C. M., Badia, M., Rubio, M., Pujol, O., & Arruga, J. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.141721 · Cited by 59
Gharbiya, M., Iannetti, L., Parisi, F., Vico, U. D., Mungo, M. L., & Marenco, M. (2014) · BioMed Research International · doi:10.1155/2014/273754 · Cited by 61
Ntjam, N. N., Thulliez, M., Paintaud, G., Salvo, F., Angoulvant, D., Pisella, P., & Bejan‐Angoulvant, T. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.0640 · Cited by 67
Curcumin, a potential therapeutic candidate for retinal diseases
Wang, L., Sun, Y., Huang, K., & Zheng, L. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200718 · Cited by 57
TOXIC VITREITIS OUTBREAK AFTER INTRAVITREAL INJECTION
NESS, T., FELTGEN, N., AGOSTINI, H., BÖHRINGER, D., & LUBRICH, B. (2010) · Retina · doi:10.1097/iae.0b013e3181baf691 · Cited by 57
Recent Advances in the Management of Neovascular Glaucoma
SooHoo, J. R., Seibold, L. K., & Kahook, M. Y. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2012.730103 · Cited by 60
Gibson, D. M. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7682 · Cited by 58
Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
Tsujikawa, A., Ellabban, A. A., Ogino, K., Ooto, Yamashiro, K., Oishi, A., & Yoshimura (2012) · Clinical ophthalmology · doi:10.2147/opth.s30907 · Cited by 56
“Previous large-scale, prospective, randomized studies of eyes with AMD showed dramatic effects of ranibizumab on CNV and subsequent improvement of visual acuity.(5,6) However, most patients with AMD require frequent injections of ranibizumab to maintain the initial visual improvement during the loading phase.”
BackgroundFerreira, A., Sagkriotis, A., Olson, M. S., Lu, J., Makin, C., & Milnes, F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133968 · Cited by 59
“Monthly dosing with ranibizumab, was shown to improve best corrected visual acuity (BCVA) by approximately seven and eleven letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 12 months in the pivotal, phase 3 trials MARINA and ANCHOR, respectively, and improvements were generally sustained up t…”
BackgroundHolz, F. G., Tadayoni, R., Beatty, S., Berger, A. R., Cereda, M. G., Hykin, P. G., Staurenghi, G., Wittrup-Jensen, K. U., Nilsson, J., Kim, K., et al. (2016) · Eye · doi:10.1038/eye.2016.90 · Cited by 62
Beyond VEGF—The Weisenfeld Lecture
Miller, J. W. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-21201 · Cited by 54
Reibaldi, M., Pulvirenti, A., Avitabile, T., Bonfiglio, V. M. E., Russo, A., Mariotti, C., Bucolo, C., Mastropasqua, R., Parisi, G., & Longo, A. (2017) · Retina · doi:10.1097/iae.0000000000001583 · Cited by 62
Peters, S., Julien, S., Heiduschka, P., Grisanti, S., Ziemssen, F., Adler, M., Schraermeyer, U., Bartz‐Schmidt, K. U., & the Tuebingen Bevacizumab Study Group (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.109702 · Cited by 57
Jackson, T. L., Slakter, J., Buyse, M., Wang, K., Dugel, P. U., Wykoff, C. C., Boyer, D. S., Gerometta, M., Baldwin, M. E., Price, C. F., et al. (2023) · Ophthalmology · doi:10.1016/j.ophtha.2023.02.001 · Cited by 55
Self-citationAskou, A. L., Pournaras, J. C., Pihlmann, M., Svalgaard, J. D., Arsenijevic, Y., Kostic, C., Bek, T., Dagnæs‐Hansen, F., Mikkelsen, J. G., Jensen, T. G., et al. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2678 · Cited by 55
Tomita, K., Tsujikawa, A., Yamashiro, K., Ooto, S., Tamura, H., Otani, A., Nakayama, Y., & Yoshimura, N. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.07.001 · Cited by 55
Ahlers, C., Golbaz, I., Einwallner, E., Dunavoelgyi, R., Malamos, P., Stock, G., Prünte, C. F., & Schmidt-Erfurth, U. M. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2759 · Cited by 55
“In contrast to conventional retinal thickness or volume parameters based on automated algorithms, SRFV obtained by manual segmentation correlated with a relative change of BCVA at weeks 2, 4, and 12 when most of the beneficial anti-VEGF effect has already been gained.(5,20) Therefore, baseline SRFV measurements appear…”
MethodModarres, M., Naseripour, M., Falavarjani, K. G., Nikeghbali, A., Hashemi, M., & Parvaresh, M. M. (2009) · Retina · doi:10.1097/iae.0b013e318198148e · Cited by 57
Ristau, T., Keane, P. A., Walsh, A. C., Engin, A., Mokwa, N., Kirchhof, B., Sadda, S. R., & Liakopoulos, S. (2013) · Ophthalmologica · doi:10.1159/000354551 · Cited by 57
Ye, F., Kaneko, H., Nagasaka, Y., Ijima, R., Nakamura, K., Nagaya, M., Takayama, K., Kajiyama, H., Senga, T., Tanaka, H., et al. (2015) · Scientific Reports · doi:10.1038/srep07705 · Cited by 55
A Review of Ranibizumab for the Treatment of Diabetic Retinopathy
Stewart, M. W. (2017) · Ophthalmology and Therapy · doi:10.1007/s40123-017-0083-9 · Cited by 53
“Ranibizumab entered clinical trials for neovascular age-related macular degeneration (nAMD) in 2000, an investigative sequence that culminated with the publication of the ANCHOR [28] and MARINA [29] trials in 2006 and approval by the US Food and Drug Administration (FDA) in the same year.”
BackgroundBrolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
Yannuzzi, N. A., & Freund, K. B. (2019) · Clinical ophthalmology · doi:10.2147/opth.s184706 · Cited by 59
von der Emde, L. A., Pfau, M., Dysli, C., Thiele, S., Möller, P. T., Lindner, M., Schmid, M. C., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-47565-y · Cited by 55
Akagi-Kurashige, Y., Tsujikawa, A., Oishi, A., Ooto, S., Yamashiro, K., Tamura, H., Nakata, I., Ueda‐Arakawa, N., & Yoshimura, N. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-1928-5 · Cited by 54
Ciulla, T. A., Pollack, J. S., & Williams, D. F. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317337 · Cited by 58
Role of microglia/macrophage polarisation in intraocular diseases (Review)
Li, H., Li, B., & Zheng, Y. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5369 · Cited by 61
Age-Related Macular Degeneration Preferred Practice Pattern®
Vemulakonda, G. A., Bailey, S. T., Kim, S. J., Kovach, J. L., Lim, J. I., Ying, G., & Flaxel, C. J. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.12.018 · Cited by 64
Channa, R., Sophie, R., Bagheri, S., Shah, S. M., Wang, J., Adeyemo, O., Sodhi, A., Wenick, A., Ying, H. S., & Campochiaro, P. A. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.09.012 · Cited by 54
Future Therapies of Wet Age-Related Macular Degeneration
Ishikawa, M., Jin, D., Sawada, Y., Abe, S., & Yoshitomi, T. (2015) · Journal of Ophthalmology · doi:10.1155/2015/138070 · Cited by 54
Ranibizumab for age-related macular degeneration
Dhoot, D. S., & Kaiser, P. K. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.660523 · Cited by 57
Self-citationFung, A. T.-C., Kumar, N., Vance, S. K., Slakter, J. S., Klancnik, J. M., Spaide, R. F., & Freund, K. B. (2012) · Eye · doi:10.1038/eye.2012.174 · Cited by 55
RIP Kinase-Mediated Necrosis as an Alternative Mechanism of Photoreceptor Death
Murakami, Y., Miller, J. W., & Vavvas, D. G. (2011) · Oncotarget · doi:10.18632/oncotarget.286 · Cited by 60
“Retinal detachment occurs in various retinal disorders, including age-related macular degeneration (AMD) [1], diabetic retinopathy [2], as well as rhegmatogenous retinal detachment.”
BackgroundInfluentialCharafeddin, W., Nittala, M. G., Oregón-Miranda, A. A., & Sadda, S. R. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20150521-03 · Cited by 54
Erie, J. C., Barkmeier, A. J., Hodge, D. O., & Mahr, M. A. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.015 · Cited by 54
Nguyen, C. L., Oh, L. J., Wong, E. H., Wei, J., & Chilov, M. N. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0785-3 · Cited by 63
Sharma, S., Khan, M. A., Chaturvedi, A., & RE-ENACT Study Investigators Group (2018) · Ophthalmologica · doi:10.1159/000488602 · Cited by 59
Shen, J., Choy, D. F., Yoshida, T., Iwase, T., Hafiz, G., Xie, B., Hackett, S. F., Arron, J. R., & Campochiaro, P. A. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24575 · Cited by 58
“VEGF is a critical stimulus for choroidal neovascularization and retinal angiomatous proliferation in these models (Kwak et al., 2000; Saishin et al., 2003a) and in patients with neovascular age-related macular degeneration (Brown et al., 2006; Rosenfeld et al., 2006).”
BackgroundAntiangiogenesis to treat cancer and intraocular neovascular disorders
Shojaei, F., & Ferrara, N. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700526 · Cited by 53
“The visual acuity benefits observed at 1 year were maintained through the second year.16 The ANCHOR trial randomized subjects with predominantly classic CNV to verteporfin PDT.17 On average, ranibizumab-treated subjects gained vision at 1 year compared with baseline, while verterporfin PDT subjects lost vision, and a…”
Does Laser Still Have a Role in the Management of Retinal Vascular and Neovascular Diseases?
Shah, A. M., Bressler, N. M., & Jampol, L. M. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.04.015 · Cited by 54
Age-related macular degeneration: current treatments
Hubschman, J., Reddy, S., & Schwartz, S. D. (2009) · Clinical ophthalmology · doi:10.2147/opth.s2094 · Cited by 60
Kumar, N., Mrejen, S., Fung, A. T.-C., Marsiglia, M., Loh, B. K., & Spaide, R. F. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.076 · Cited by 56
Grunwald, J. E., Daniel, E., Ying, G.-S., Pistilli, M., Maguire, M. G., Alexander, J., Whittock-Martin, R., Parker, C. R., Sepielli, K., Blodi, B. A., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.013 · Cited by 53
Nagai, N., Kubota, S., Tsubota, K., & Ozawa, Y. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2014.05.015 · Cited by 55
“The positive effects of anti-VEGF drugs are well documented [3,4], while non-responsive cases are also reported [5].”
BackgroundFreund, K. B., Balaratnasingam, C., Dhrami‐Gavazi, E., McCann, J., & Ghadiali, Q. (2015) · Clinical ophthalmology · doi:10.2147/opth.s80040 · Cited by 61
Vascular endothelial growth factors in retinal and choroidal neovascular diseases
Kinnunen, K., & Ylä‐Herttuala, S. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.532150 · Cited by 62
KSI-301: antibody biopolymer conjugate in retinal disorders
Chandrasekaran, P. R., & Madanagopalan, V. (2021) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414211027708 · Cited by 65
Ng, B., Kolli, H., Ajith-Kumar, N., Azzopardi, M., Logeswaran, A., Buensalido, J., Mushtaq, B., Chavan, R., & Chong, Y. J. (2024) · Life · doi:10.3390/life14020193 · Cited by 55
Dirani, A., Ambresin, A., Marchionno, L., Decugis, D., & Mantel, I. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.06.025 · Cited by 59
Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization
Introini, U., Casalino, G., Querques, G., Gimeno, A. T., Scotti, F., & Bandello, F. M. (2012) · Eye · doi:10.1038/eye.2012.75 · Cited by 52
Chen, F. K., Uppal, G., MacLaren, R. E., Coffey, P. J., Rubin, G. S., Tufail, A., Aylward, G. W., & da Cruz, L. (2008) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2009.01915.x · Cited by 58
“Recent advances in intravitreal anti-vascular endothelial growth factor therapies have shown promise in the treatment of these lesions with over one-third of patients gaining three lines or more of visual acuity (VA) at 12 month which was maintained at 2 years after initiation of monthly injections.(1,2) However, the…”
BackgroundLocal Tolerance and Systemic Safety of Pegaptanib Sodium in the Dog and Rabbit
Foy, J. W.-D., Rittenhouse, K. D., Modi, M., & Patel, M. (2007) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2006.0149 · Cited by 53
“2,3 In addition to pegaptanib sodium, other VEGF inhibitors currently being used for IVT treatment of AMD include ranibizumab, 7,8 off-label bevacizumab, 9,10 and the investigational agent, VEGF Trap.”
Aflibercept in wet age-related macular degeneration: a perspective review
Ohr, M. P., & Kaiser, P. K. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312446007 · Cited by 58
Self-citationLoewenstein, A. (2007) · Retina · doi:10.1097/iae.0b013e318050d2ec · Cited by 52
Dong, A., Shen, J., Zeng, M., & Campochiaro, P. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012859108 · Cited by 54
Bilateral Simultaneous Intravitreal Injections in the Office Setting
Bakri, S. J., Risco, M., Edwards, A. O., & Pulido, J. S. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.02.013 · Cited by 52
Vascular endothelial growth factor inhibition in uveitis: a systematic review
Gulati, N., Forooghian, F., Lieberman, R. M., & Jabs, D. A. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.177279 · Cited by 57
“This agent was approved for use in all types of neovascular AMD after randomised controlled clinical trials documented not only prevention of further visual loss, but also an improvement in visual acuity in a substantial proportion of patients.(1) 2 Bevacizumab, a monoclonal antibody targeting VEGF that was initially…”
MethodTargeting neovascularization in ischemic retinopathy: recent advances
Al‐Shabrawey, M., El‐Sherbiny, M., Nussbaum, J. J., Othman, A., Megyerdi, S., & Tawfik, A. M. (2013) · Expert Review of Ophthalmology · doi:10.1586/eop.13.17 · Cited by 59
Divergence in the Lived Experience of People with Macular Degeneration
McCloud, C., Khadka, J., Gilhotra, J. S., & Pesudovs, K. (2014) · Optometry and Vision Science · doi:10.1097/opx.0000000000000320 · Cited by 59
Wecker, T., Grundel, B., Reichl, S., Stech, M., Lange, C., Agostini, H. T., Böhringer, D., & Stahl, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-38934-8 · Cited by 54
Age-related macular degeneration
Ayoub, T., & Patel, N. (2009) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2009.080298 · Cited by 59
Interventions for diabetic macular oedema: a systematic review of the literature
O’Doherty, M., Dooley, I. J., & Hickey-Dwyer, M. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.144550 · Cited by 52
“Ranibizumab (Lucentis; Genentech, South San Francisco, California) is another anti-VEGF agent used for treatment of neovascular AMD.(50) 51 and may also be useful for DR and DMO.”
BackgroundAltaweel, M. M., Daniel, E., Martin, D. F., Mittra, R. A., Grunwald, J. E., Lai, M. M., Melamud, A., Morse, L. S., Huang, J., Ferris, F. L., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.020 · Cited by 51
AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration
Liu, Y., Fortmann, S. D., Shen, J., Wielechowski, E., Tretiakova, A., Yoo, S., Kozarsky, K., Wang, J., Wilson, J. M., & Campochiaro, P. A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.002 · Cited by 51
“In initial clinical trials, treatment-naive subjects with recent onset of NVAMDwere givenmonthly intravitreous injections of a VEGF-neutralizing protein, and 34%–40% of subjects experienced at least a 15-letter improvement in best-corrected visual acuity (BCVA), a large and clinically meaningful benefit, that was main…”
BackgroundGoldstein, J. E., Bradley, C., Gross, A. L., Jackson, M., Bressler, N. M., & Massof, R. W. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.5.10 · Cited by 55
Heimes, B., Lommatzsch, A. P., Zeimer, M. B., Gutfleisch, M., Spital, G., Dietzel, M., & Pauleikhoff, D. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1524-5 · Cited by 51
“In phase III trials the benefit of anti-VEGF therapy with ranibizumab (Lucentis) in patients with exudative AMD was already evident after the first 3 months of treatment [1, 6, 8, 9].”
BackgroundInfluentialGerding, H., Loukopoulos, V., Riese, J., Hefner, L., & Timmermann, M. (2011) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-011-1636-6 · Cited by 51
“The promising results of the MARINA and ANCHOR studies [ 3 , 4 ]h ave set the benchmark for the treatment of AMD treatment by demonstrating gains of 7.2 and 11.3 letters at 12 months.”
BackgroundResultInfluentialDevelopment of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians
Keane, P. A., & Sadda, S. R. (2012) · Journal of Ophthalmology · doi:10.1155/2012/483034 · Cited by 51
“In 2006, ranibizumab was licensed for use in the United States following publication of the MARINA and ANCHOR studies [79, 80].”
BackgroundMethod
Metadata
- Authors
- Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S.
- Affiliations
- Houston Methodist (US)
- Cleveland Clinic (US)
- Retina Care Specialists (US)
- Ophthalmic Consultants of Boston (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1432-1444
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085712747
- Cited by
- 3,522
- References
- 19
- Citations by year
- 2026: 97 · 2025: 110 · 2024: 115 · 2023: 97 · 2022: 117 · 2021: 189 · 2020: 178 · 2019: 140 · 2018: 154 · 2017: 170 · 2016: 188 · 2015: 209 · 2014: 218 · 2013: 247 · 2012: 257
- FWCI
- 161.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, verteporfin, neovascular age-related macular degeneration, anti-VEGF therapy, photodynamic therapy, intravitreal injection, visual acuity, endophthalmitis, uveitis
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Visual Acuity, Photosensitizing Agents, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.